New hope for kids with aggressive nerve cancer: immune-boosting NK cell combo enters final trial phase

NCT ID NCT07375563

Recruiting now Disease control Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated Apr 25, 2026 · Updated 12 times

Summary

This study tests a new treatment for children with high-risk neuroblastoma that has not responded to standard therapy or has come back. The approach combines chemotherapy, immunotherapy, and the patient's own natural killer (NK) cells to help the immune system fight the cancer more effectively. The goal is to improve tumor shrinkage and survival rates. The trial is currently recruiting 5 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITING

Moscow, 117198, Russia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GANGLIONEUROBLASTOMA NEUROBLASTOMA (NB)